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ABSTRACT 
The aim of this research was to develop and evaluate liquisolid compacts of Voriconazole a BCS class II drug. The series of formulations 
containing Voriconazole drug were formulated by using aerosil a colloidal silicone dioxide and avicel PH microcrystalline cellulose in different 
ratios by using suitable solvent. Solubility studies were performed in propylene glycol and polyethylene glycol (PEG-200, 400, 600) for the 
choice of the best nonvolatile liquid to dissolve Voriconazole. On the basis of the solubility data PEG 600 was chosen as a good solvent for the 
Voriconazole. Voriconazole was dissolved in solvent PEG 600 for the preparation of solution of drug. Formulated compacts were evaluated for 
all post compression parameters and the in-vitro drug release study was carried out. All the formulations have shown a very good drug release 
in  15 min except compressibility problems due to higher loading factor of liquid vehicle for the formulations. The selected formulation FV10 
containing 30% of drug solution has  shown good drug release of 100.2.% in 15  min compared to dissolution of  pure drug and marketed tablet 
which shown 58.5.5%  and 70..6 % respectively.No interactions were found  between drug and polymers in FITR as well as DSC. XRD of selected 
formulation shows that drug present in the formulation is in amorphous form.  
Keywords: Voriconazole HCl, Avicel PH, Aerosil 200, Poly-Ethylene Glycol 600, liquisolid compacts.  
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INTRODUCTION  
The oral administration is the route of choice and is the very 
much preferred route for administration of drug due to more 
patient fulfillment (or) acceptance in the drug development. 
Because of some associated problems caused by this route of 
administration, this is complicated to achieve the plasma 
drugs concentrations. The drug solubility is a biggest 
problem and it is the most important to attain the required 
amount of drug into the blood.1 
The drugs have incomplete bioavailability which is less 
water soluble and having less dissolution rate. The challenge 
of slightly solubility of drug in water is to develop the 
solubilization and dissolution of drug. Various types of 
techniques that can be utilized to develop the solubilization 
of less water soluble and water insoluble active constituent, 
like reduction of particle size into microns, freeze drying, 
dispersion of drug into solubilising agent, using complex 
forming agents, co solvents, chemically modifications, 
adjusting pH, solubilization with surface active agents, Solid 
solution, encapsulation of drug in liquid form into the soft 
gelatin capsule, formation of salt. The techniques like these 
were introduced to develop the drug solubility and to boost 
the absorption of drug and drug bioavailability. The 
liquisolid compact is admissible fluidly and is a compressible 
powder form of liquid medicament. A liquid portion, which 
may be an oily liquid medicament, suspensions or solutions 
of poorly water soluble drug in an appropriate solvent 
vehicle of nonvolatile, is included in the carrier agent of 
porous nature. During the saturation point of carrier with 
solvent, formation of solvent layer takes place over the 
surface of particles which then get adsorbed fatly by the 
coating particles of fine nature. In this way, a clearly dry easy 
flowing powder for compressibility is obtained. The 
concentrations of carrier, coating material, disintegrant, 
lubricant and glidant are optimized to obtain a non-stick 
readily compressible mixture. These techniques were 
introduced to progress the drug solubility molecule also to 
enhancement of absorption and also drug bioavailability. 
The method of solid dispersion is significant for the 
enhancement of drug solubilization, its wetting property, 
and to boost the drug solubility and bioavailability. In order 
to solve all such type of problems, the “Liquisolid Technique 
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"was developed which may called as the Technology of 
Powder solution 
Hence main objectives of this present study were to carry 
out the solubility enhancement technique for the BCS class II 
drugs by using the liquisolid compact technique.2 
MATERIALS AND METHODS 
Materials: VoriconazoleHcl is received as gift sample from 
Gland pharmaHyderabad colloidal silicone dioxide (Aerosil 
200), Microcrystalline cellulose (Avicel PH 101) are 
received from Microlabs Bangalore and solvents like 
Propylene Glycol ,PEG solvents are used of laboratory grades 
purchased from SD fine chemicals Mumbai. All other 
solvents and reagents were used as analytical grade. 
Determination of solubility of Voriconazole drug: 
Solubility studies were performed in propylene glycol and 
polyethylene glycol (PEG-200, 400, 600) for the choice of the 
best non volatile liquid to dissolve Ezetimibe. Saturated 
solutions have been developed by the addition of surplus 
medications to solvent vehicles and stirring in a shaker 
incubator for 48 hours at 25 º C ± 1 º C. Following this stage 
the filtration was done  by a filter of 0.45 µm Millipore, by  
diluting using distilled water and done analysis by a the help  
of UV visual spectral in the wavelength of 255 nm against the 
blank in a solvent of non volatile in nature is the most 
significant  quality of liquisolid system. The drug 
solubilization helps in the molecular dispersion in non 
volatile solvents like that may get improvement in the rate of 
dilution. On the basis of the solubility data PEG 600 was 
chosen as a good solvent for the Ezetimibe. 
Preparation of liquisolid compacts: 
Voriconazolewas dissolved without changing solvent PEG 
600  for the preparation of solution of drug. The combination 
of coating and carrier materials transferred Avicel PH102 as 
carrier and colloidal silicon dioxide (Aerosil 200) as the 
coating adjuvanct which was then added to the solvent and 
mixed in ceramic mortar to avoid over-trituratio and reduce 
particle size. The blend was done in three phases; in the first 
phase, the drugs are slowly mixed to get    even distribution 
of solvent medications. In the next stage, the blend was 
spreaded as a homogeneous coat on the surface and 
remained in position for a some minutes of interval. In last 
phase addition of 5% of disintegrating agent 
(Croscarmellose) was done to the granules or powder and 
mixed completely. The last blend is compressed into 
compacts by using 12 mm punches of round flat type in 16 
station rotary tablet machine. 3 
Evaluvation of liquisolid compacts 
Determining the drug solubility   
Solubility studies had been conducted to choose the higher 
solubilization of the pure drug model in solvents like 
nonvolatile nature, which includes drugs solubilized in 
various solvents of nonvolatile. The quantities of excess net 
drugs were added to non-volatile solvents, followed by a 
transfer of saturation solution to rotary transformers for 48 
hours at 25oC under continuous vibration. After a period of 
48 hours the saturated solution is filtered by using a filter 
like Millipore of 0.45 μm and analyzed. 
Solubility studies were performed in the solvents propylene 
glycol and polyethylene glycol (PEG-200, 400, 600) to select 
the best non-volatile solvent to dissolve Voriconazole. 
Saturated solutions have been developed by the addition of 
excess medications to vehicles and stirring in a shaker 
incubator for 48 hours at 25 º C ± 1 º C. After this period the 
solutions were filtered through a filter of 0.45 µm Millipore, 
diluted with distilled water and distributed by a double 
radius of visible UV spectral spectrum in the wavelength of 
255 nm.  
Determination of angle of slide 
Many standard liquid compounds/powder mixtures 
containing 10 grams of carrier or coating material are 
prepared with increasing amounts of liquid vehicles. To 
measure the angle of slide, the liquid mixtures/powder of 
Voriconazole was placed on polished metal plates, and then 
gradually imbalanced until the liquid/powder was slided on 
the verge of slipping. The angle that is formed between the 
panel and the horizontal surface is defined as the angle of 
the slide.  
Calculation of the loading factor: 
In the liquisolid system, the microcrystalline cellulose and 
aerosol could only keep definite amount of solvent by the 
maintenance of the satisfactory flow also compressibility 
characteristics according to the ratio used. The ratio of 
powder found in was R where  of powder or 
granules are stated like fraction of carrier adjuvant (q) and 
the coating adjuvant materials (q) of the system. It is 
possible to set up the Voriconazole liquisolid system, which 
is transferable with an acceptable flow and the possibility of 
compression if it does not exceed the maximum fluid limit in 
the carrier's material. This nature of  liquid is called a liquid 
or solvent loading factor (LF) and  may be stated as the 
weight fraction of solvent medicine (W) and the adjuvanct 
carrier (q) in the method  where LF = w/q. For computation 
of the liquid or solvenht load factor, solvents (liquid drugs 
without medication) with nonvolatile have been included to 
10gm of carrier materials and collected for 1 minute then in 
this material addition of coating material done and mixed. 
The formulations are designed for Voriconazole liquisolid 
systems according to the mathematical model described by 
Spireas et al. According to the theories of liquisolid tablets, 
the powder carrier and coating agents can only hold definite 
amounts of solvents and maintains an acceptable flow and 
compressible force. The fraction of powder in ratio R is 
known as 
R = Q/q ——— (1) 
 
 Where R is the fraction of carrier weight (Q) and (q) of the 
coating material found in the formulations.The liquid load 
factor (LF) is defined as the weight fraction of the liquid drug 
(W) to the weight of the carrier (Q) in the system, which 
must be present in the flowing system and the 
compressibility. 
LF = W/Q ——— (2)         
  LF = W/Q ——— (2) 
The ability to flow liquid retention (θ value) of powder 
absorbent material was used to calculate the required 
quantities of components. Therefore, the powder rates R and 
the liquid load factor LF of the formulations are related to 
the following way 
Loading factor = Φ C A + Φ CO * 1 / R. 
W = wt. of liquid drug, Q = wt. of carrier material 
Q = W/LF-(4) q = Q/R-(5) 
Where, Q is carrier agent and q is the coating agent.4 
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Evaluation of VoriconazoleLiquisolid tablets (post 
compression parameter) 
The compression parameters of the Voriconazole Liquisolid 
tablets are as follows. 
Tablets Size and shape: 
 The size of tablets and tablets shapes can be explained as 
dimensions watched and controlled. It is found by the 
machine throughout the process of compression. 
Determination of Moisture of Granules: 
 The granules or powders must have enough strength to 
resist normal process during handle of mixture and 
incorporation processes without production of big amount 
of fine dust. In some size decreasing process throughout the 
process of condense in the tablets is useful to represent the 
areas of the fresh surfaces required for best possible link to  
put so the dampness content is the very vital thing for fine 
medicinal products. 
Weight Variation Test:  
As per the USP the test for tablets weight variations test of 
the tablets Voriconazole Liquisolid is made by weighing 20 
compacts independently by calculated common weights and 
compared the weight of individual tablet on mean weight. 
The variation in weights of tablets in test is denominated by 
percentage. The formula used for same weight variation test 
= (iw-aw)/aw X 100% where, iw = Individual or single 
weight of tablet. aw = average or mean  weight of tablet. 
According to USP the tablet comply with the tests if no extra 
than 2 out of  single weights diverge as of the mean mass by 
additional than the proportion divergence as shown in 
table.5 
Drug content uniformity:  
Standard preparation: About 20 mg of Voriconazole was 
weighed accurately and shift to a flask of 50 ml. and dissolve 
then dilute and fill up to the volume with the Phosphate 
solution 7.4 pH and mixed. 
Preparation of sample solution: Five tablets were taken 
powdered and weighed into powder. The powder equal to 
20 mg is taken by weighing accurately. Drug Voriconazole 
powder was transferred to a flask of 50 ml and made to 
dissolve in a 7.4 pH phosphate buffer. Sonication is done by 
keeping for 30 minutes and filtered using membrane filter 
0.45. It is then dissolved and diluted to the mark. The 
absorption of both after the appropriate dilutions was 
measured in a UV-visible spectrophotometer at 255 nm of 
standard preparation and the preparation of the sample at 
7.4 pH phosphate solutions. The repetition of method was 
done for 3 times.   
Thickness: The tablet thickness of individual tablets was 
found with a sliding caliper scale of 5 or 10 tablets, where 
their total thickness was measured. The thickness of the 
tablet must be checked within a variation of ± 5% of a 
standard expressed in mm. 
Hardness Test: 
For this test tablet hardness tester, Monsanto hardness 
equipment is used to evaluate the hardness of tablet was 
used. The equipment contains a drum and a compressor 
spring which is held in between two divers. The piston is 
located to make contact with the tablet and receives reading 
at zero level. The piston which is upper side is moved with 
force in opposition to a spring by rotating a thread lock till 
the tablet breaks. When the compression of spring is done, 
an indicator reads alongside a meter in the drum to point out 
strength. The force of the break is noted in a k.g. Ten 
Voriconazole liquisolid compacts are compressed and 
measured their hardness and the permissible range in 
between 4-6 kg (40-60 N) if not or else noted. 
Friability test: The test for Friability of tablets can find 
experimentally by Roche Friabilator. To test weight of 
twenty Voriconazole liquisolid compacts are taken and kept 
in the Friabilator and then rotated at 25 Rotations per 
minute until 240 seconds. The tablet weight is noted again 
by dusting. The variation of two weights in tablets is noted 
to compute the friability and the reading and is noted. This 
was found by using the formula: 
 
 
Where, IW = initial weight of compacts   FW = final weight of 
compacts. As per USP the compacts that loss is lesser than 
0.5% to 1% (after 100 rotations) of their weights are usually 
considered as satisfactory. 
Disintegration test: 
USP devices containing 6 glass or plastic tubes which are 3 
inches in legth, open at the top, and covered by 10 no. net 
screen towards the base end of the basket stand apparatus. 
For  checking  the disintegrate time, a Voriconazole liquisolid 
compact  is kept on every tube and the set of  basket is 
placed in a specific media at 37 ± 2 ° C, as the compacts 
leftovers 2.5 cm under the liquid surface in the movement 
towards ascending and descending is no nearer than 2.5 
centimeters from the base of the container. A model machine 
device is utilized to move the basket assemble which 
contains the tablets top and bottom throughout the space of 
5 to 6 cm. At a occurrence of 28 to 32 revolutions per 
minute. Plastic discs of perforated may be used in the study. 
The compacts are kept at the top of s and transmit a rough 
stroke on the tablets. Discs may be or may not be necessary 
or provide additional sensitivity to the study, but these are 
helpful for floating of compacts or tablets. Function the 
device for the specific time (900seconds for compacts of un 
coated, if not or else acceptable and permitted) 
The compacts comply as per the test if the compacts are 
dissolved, and all drog particles pass through the mesh at 
the specified time. If filtrate remains, it should have a soft 
mass without a clearly stable nucleus. The compacts   
comply with the study as per the USP, if all the compacts 
have been fully dissolved. If the 1 or 2 compacts fail to 
dissolve totally, repetition of the test should be done for 12 
supplementary compacts. If the condition is not met then not 
lesser than 16 of the 18 compacts are to be tested.6 
In vitro dissolution study of Voriconazoleliquisolid 
compacts: release of medications from liquesolid tablets has 
been determined using the USP type II (paddle).  Followed 
the test through three steps if not the outcome match both 
S1 and S2. The Q amount is the particular quantity of active 
constituent dissolved, noted in a percentage of the nominal. 
5% 15% and 25 % values and are named content modifiers, 
so that these values and Q are under the same conditions.  
Standard solution: 0.1 N HCl 
Size 500 ml;  
Temperature maintained 37°c ± 0.5 °c  
Speed of paddle: 50 rpm.  
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Process: 5 ml of the media were withdrawn every time at the 
appropriate intervals of 10, 20, 30 and L. 45 and replaced by 
a fresh solution. After withdrawal of the sample filtration 
was made and analyzed after dilution using a double beam 
of UV spectrophotometer at 255nm.7 
RESULT AND DISCUSSION 
Standard calibration curves of Voriconazoledrug in 0.1 
N HCl: 
The calibrations curve of Voriconazole drug was plotted by 
the absorbance v/s concentrations. The max of 
Voriconazole drug in in 0.1 N HCl was determined at max 
255 nm. The values of absorbance are shown in table. The 
standard calibrations curve of Voriconazole is in the Beer's 
range between 10-60 g/ml. 
Determination of solubility of Voriconazole drug:  
Solubility studies were performed in propylene glycol and 
polyethylene glycol (PEG-200, 400, 600) for the choice of the 
best non volatile liquid to dissolve Ezetimibe. Saturated 
solutions have been developed by the addition of surplus 
medications to solvent vehicles and stirring in a shaker 
incubator for 48 hours at 25 º C ± 1 º C. Following this stage 
the filtration was done  by a filter of 0.45 µm Miilpore, by  
diluting using distilled water and done analysis by a the help  
of UV visual spectral in the wavelength of 255 nm against the 
blank in a solvent of non volatile in nature is the most 
significant  quality of liquisolid system. The drug 
solubilization helps in the molecular dispersion in non 
volatile solvents like that may get improvement in the rate of 
dilution. On the basis of the solubility data PEG 600 was 
chosen as a good solvent for the Ezetimibe. 
Determination of Angle of slide: 
Many standard solvent compounds or powder mixtures 
which contain 10 grams of carrier   or coating material are 
prepared with increasing amounts of liquid vehicles. To 
determine the angle of slide, the solvent or powder prepared 
from Voriconazole kept on metal plate which is polished, and 
then slanted steadily until the liquid or powder mixture was 
get slided. The angle that is formed between the panel and 
the surface which is horizontal is stated as the angle of slide 
(h).  
The Angle of repose: 
 The angle of repose of these powders is formed due to the 
effect of the inner particles of strong friction. The most 
cohesive molecules in nature have a higher angle of repose. 
Angle of repose smaller than thirty degrees shows good flow 
nature from a 40 degree angle and above shows poor flow. 
Formulations with a angle of repose superior than 40 are not 
satisfactory (F1-F12 and F13-f16 formulations) 
combinations, F10 and F11 shown 27 degrees, and 28 
degrees respectively, showed a good flow, but the F10 
formula necessary in a larger quantity of carrier adjuvant 
that improved the size of the compact to 455 mg. So the F10 
preparation was chosen for compression. 
Bulk density and tapped density:  
The acceptable range and values summarized in table 
indicate the values for all combinations from F1 to F16 in 
Voriconazole formulations. This outcome helps to calculate 
the percentage of the powder compressibility within the 
acceptable limit. 
Carr’s Index: Based on these parameters, the F11 
formulation was chosen for further evaluation. Formulation 
F10 showed Carr index 22.47 and Hausner ratio of 1.15 to 
the total weight of the tablet of 455 mg. 
Post compression Parameters of Voriconazole Liquisolid 
compacts: 
Hardness: The liquisolid system must have sufficient 
hardness to prevent breakage during manipulation, and also 
must be disintegrate. The formulation of F10 also showed a 
very good hardness of about 4.5 kg/cm 2.  
Thickness: The thickness values of F1 to F16 formulas are 
almost uniform in all formulas. 
Friability test: The friability results of the Voriconazole 
liquisolid compacts have been found within the approved 
range (< 1%) and formulations from F1 to F16 and possess 
good mechanical strength. 
Weight variation test: The percentage of tablets weight 
variations were found for the formulations F1 to F16. The 
values observed were within the acceptable limit. 
Drug content uniformity: The liquisolid tablets were 
evaluated to standardize the drug content by selecting ten 
compacts randomly. The compacts were powdered then 
weighed 100 mg of the powder then shifted ed in a 
volumetric flask of 100 ml, and the content of drug was 
estimated by spectrophotometrically at 255 nm (Indian 
Pharmacopeia) The drug content for compacts of all the 
formulations ranges in between 96.6-99.9%. The results 
indicates that the tablets active contents of all the 
preparations were found to be identical and contains right 
dose of the active ingredients. 
Disintegration time: The disintegration time of the tablets 
is given in Table 65 and was found to be 115 and 125 
seconds for the FV10 and FV11 formulation. For 
formulations FV1 to FV9 and formulations FV12 to FV16 was 
observed to be 215 to 250 seconds. 
Dissolution study: Dissolution studies of all formulations 
from FV1 to FV16 were carried out in 0.1N HCl. There is no 
great difference in the patent of all formulations due to the 
good solubility of the drug in the liquid or solvent except for 
the compressibility problems due to the higher loading 
factor of the liquid vehicle for preparations. All formulations 
showed very good drug release in 15 minutes. The selected 
formulation of FV10 containing 30% of a drug solution has 
shown good drug release of 100.20% over 15 minutes as 
compared to the dissolution of the pure drug and the tablet 
marketed which showed 58.5% and 70.60% respectively. 
The drug release data obtained for the FV10 formulation 
together with the pure drugs and tablets marketed. 
Drug-Excipient Interactions: 
DSC thermogram: DSC of pure Voriconazole was showed a 
sharp peak of endotherm at 188.670C with respect to its 
melting point, indicates the crystal character of the drug. 
DSC thermo grams of liquisolid compacts indicated broad 
peaks at 128.560C, indicating a decreasing in the crystal 
nature of drug and its transform to amorphous form. A slight 
shift in the drug melting peaks indicating dissolution of drug 
in the non volatile liquid PEG 600 before reaching its fusion 
temperature. It was concluded that the presence of the drug 
affects the lattice energy of the crystalline polymer leading 
to shifting of the peak. The vanishing of drug peak in 
formulations into a liquisolid compacts indicate the absolute 
inhibition of all drug thermal characters certainly indicates 
the formation of an solid solution of amorphous. No other 
interactions were observed in between the drug and 
excipients. 
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FT-IR spectra of VoriconazoleLSC: 
FTIR spectroscopy was utilized for the analysis of the 
changes in structure and interaction possibilities of between 
the drug and Liquisolid compacts of Ezetimibe. The 
characteristic peaks of Voriconazolewas found to be 3200, 
2400, 1200,800 cm-1.  The FTIR spectrum of Liquisolid 
compacts of Voriconazole showed its characteristic IR 
absorption peaks at 3300, 2400, 1100, 650 cm-1. These 
spectra observations revealed no any interactions among the 
carrier and drug used. 
X-Ray Diffratrometry (XRD) of   VoriconazoleLSC: The X-
ray diffractogram of the Voriconazole Drug, Formulation F11 
and Physical mixture. Voriconazole shows sharp peaks at 
16°, 17.5° and 19° and 19.5°. The nonexistence of 
distinguishing peak of Voriconazolein liquisolid compacts 
shows that drug is completely transformed into amorphous 
or solubilized appearance. The nonexistence of crystal 
nature of the drug in the liquisolid compacts may be due to 
the effect of solubilisation in the solvent material which was 
absorbed in the carrier material and adsorbed on the coating 
materials. The liquisolid system and physical mixture 
preparations have the same diffracting pattern and found no 
other peaks. The amorphization or solubilisation of 
Voriconazole has increased the dissolution rate. 
Stability Study: The stability study was conducted for F10 
formulations stored in 40°C/75% RH for 30 days.  The 
various parameters were studied such as hardness, friability, 
drug contents uniformity, in vitro dissolution. There was 
not much variations observed in any parameters throughout 
study period of time. 9, 10 
CONCLUSION 
In this research, attempt was made to formulate liquisolid 
compacts by the use of Avicel PH and Aerosil 200, as carrier 
and coating material .Suitable solvent propylene glycol was 
selected based on solubility parameter and used as best 
solvent to dissolve Voriconazole. Liquid loading factor was 
calculated based on the solubility property of drug into the 
solvent. The prepared liquisolid powders are subjected to 
precompression parameters and compressed into the 
compacts. The post compression parameters of compacts 
were evaluated   In vitro dissolution of compacts shown a 
very good drug release except compressibility problems in 
formulations with high liquid load factor other than 
Formulations F10 and F11 having low  liquid load factor. It 
was found that formulations F10 and F11 have shown a very 
good release and formulations.F10 when compared to the 
pure drug and marketed product has shown a good release 
and was selected as a final formulation based on the total 
weight of the tablets and subjected to the final 
characterization along with stability study. Thus this 
technology has shown a potential drug release for poor 
water soluble drugs and proves to be a potential approach 
for the enhancement of solubility of poor water soluble 
drugs thus enhancing the bioavailability. 
 
 
Table 1: formulation of liquisolid compacts of voriconazole 
Liquisolid system* Drug concentration 
in PG  (% w/w) 
R R=Q/q Lf Lf=W/Q Avicel PH 102 
Q = W/Lf 
Aerosil 200 
q=Q/R 
Formulation wt  
(mg) 
FV1  5 0.835 400 80 575 
FV2 15% (335ml) 10 0.675 500 50 650 
FV3  15 0.55 600 40 750 
FV4  20 0.475 700 35 850 
FV5  5 0.83 300 60 440 
FV6 20%(250ml) 10 0.625 400 40 530 
FV7  15 0.5 500 33.3 630 
FV8  20 0.415 600 30 740 
FV9  5 0.67 150 30 245 
FV10 40%(125ml) 10 0.4 250 25 345 
FV11  15 0.28 350 23.33 455 
FV12  20 0.22 450 22.5 565 
FV13  5 0.67 100 20 175 
FV14 60%(85ml) 10 0.33 200 20 285 
FV15  15 0.22 300 20 400 
FV16  20 0.165 400 20 505 
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Table 2.Precompression parameters of liquisolid powders : 
F No Angle of 
Repose 
Bulk 
Density 
Tapped 
Density 
Carr’s 
Index 
Hausner’s 
Ratio 
 
FV1 42 0.79 0.95 20.22 1.20 
FV2 41 0.78 0.95 22.22 1.21 
FV3 41 0.75 0.91 20.07 1.21 
FV4 40 0.72 0.91 21.00 1.26 
FV5 41 0.70 0.88 21.50 1.25 
FV6 40 0.73 0.91 20.87 1.24 
FV7 40 0.70 0.90 22.22 1.26 
FV8 39 0.70 0.91 23.07 1.30 
FV9 38 0.72 0.92 21.97 1.27 
FV10 27 0.65 0.75 22.47 1.15 
FV11 28 0.69 0.79 10.12 1.14 
FV12 32 0.69 0.85 13.50 1.23 
FV13 34 0.71 0.90 21.34 1.26 
FV14 33 0.70 0.91 22.47 1.30 
FV15 31 0.69 0.90 20.22 1.30 
FV16 30 0.71 0.89 22.22 1.25 
 
Table 3: Post compression parameter of liquisolid compacts 
Formulation Code Hardness (kg/cm2) Weight Variation % Friability Thickness 
 
mm 
FV1 4.5 575±3% 0.30 4.55±0.2 
FV2 4.5 650±2.5% 0.30 4.93±0.1 
FV3 4.0 750±1.5% 0.45 5.14±0.2 
FV4 4.5 850±1% 0.35 5.85±0.6 
FV5 4.0 440±2% 0.45 4.15±1.5 
FV6 4.0 530±1.5% 0.80 4.25±0.6 
FV7 4.0 630±2% 0.60 4.89±0.5 
FV8 3.5 740±2.5% 0.50 5.15±0.25 
FV9 4.0 245±4% 0.40 3.5±0.12 
FV10 4.5 345±2.5% 0.45 3.75±0.15 
FV11 4.5 455±2% 0.45 4.10±0.25 
FV12 4.0 565±2% 0.40 4.45±0.35 
FV13 3.5 175±4.5% 0.50 3.25±0.15 
FV14 3.0 285±3% 0.55 3.65±0.14 
FV15 3.5 400±2% 0.55 4.00±0.15 
FV16 3.5 505±3% 0.70 4.2±0.22 
 
Table 4: Disintegration and drug content of liquisolid compacts 
Formulation 
Code 
Disintegration 
time (sec) 
Drug Content  
Uniformity (%) 
FV1 325 95.6±0.25 
FV 2 328 96.7±0.85 
FV 3 330 98.4±0.66 
FV 4 300 97.3±0.56 
FV 5 355 99.5±0.50 
FV 6 345 97.70±0.55 
FV 7 350 95.0±0.45 
FV 8 320 98.9±0.75 
FV9 280 99.1±0.85 
FV10 115 96.5±0.80 
FV11 125 97.0±0.90 
FV12 285 98.2±0.25 
FV13 310 99.0±0.10 
FV14 325 98.5±0.25 
FV15 336 98.3±0.50 
FV16 340 99.0±0.76 
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Figure 1: in vitro dissolution of formulation fv10, marketed tablet and pure drug 
 
Figure 2: FTIR of voriconazole drug 
 
Figure 3: FTIR of voriconazole formulation 
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Figure 4: DSC of voriconazole drug 
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Figure 5: DSC of voriconazole lsc formulation 3
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Figure 6:        x-ray diffraction pattern of ezetimibe 
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Figure 7: X ray diffraction of Voriconazole drug 
8
Operations: Smooth 0.250 | Background 0.000,1.000 | Import
File: SAIFXR171227C-08(8).raw - Step: 0.020 ° - Step time: 29.1 s - WL1: 1.5406 - kA2 Ratio: 0.5 - Generator kV: 40 kV - Generator mA: 35 mA - Type: 2Th/Th locked
Lin
 (C
ou
nt
s)
0
1000
2000
3000
 
 
2-Theta - Scale
3 10 20 30 40 50 60 70 80
 
Figure 8: X-Ray Diffraction pattern of VoriconazoleLSC formulation without drug 
Table 5: Stability study of optimized formulation FV10 at 40 0C/75% RH 
F. Code 
After 
time 
(in days) 
Hardness 
(kg/cm
2
) 
DT 
time (sec) 
Thickness 
Drug content 
 
Friability % 
 
FV10 
10 4.5 290 4.10±0.25 99.5±0.80 0.45 
20 4.5 295 4.10±0.25 99.5±0.00 0.40 
30 4.5 280 4.10±0.25 99.5±0.00 0.40 
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